Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05096754 · ClinicalTrials.gov registry record

OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval Study

A clinical trial of Liver Transplant, sponsored by TransMedics.

Completed
Registry status
74
Enrollment target
11
Study locations

NCT05096754 is a study of Liver Transplant that has completed, run by TransMedics. The registered enrollment target is 74 participants, below the 5,454-participant average among 19 other Liver Transplant trials with a reported enrollment target (99% lower). The trial reports 11 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05096754, a study of Liver Transplant, has completed, sponsored by TransMedics.

COMPLETED
Registry status
74 participants
Enrollment target
11
Study locations

Study Summary

Post-approval observational study of subjects that were enrolled and transplanted in the OCS Liver PROTECT CAP.

Conditions Studied

Interventions

  • DEVICE OCS Liver

Study Locations (11)

California

  • Scripps - La Jolla
  • University of California San Diego - La Jolla
  • University of California San Francisco - San Francisco

Texas

  • University of Texas Southwest - Dallas
  • Houston Methodist Hospital - Houston
  • The University of Texas Health Science Center at San Antonio - San Antonio

Maryland

  • Johns Hopkins - Baltimore

Massachusetts

  • Massachusetts General Hospital - Boston

Nebraska

  • University of Nebraska Medical Center - Omaha

New York

  • Mount Sinai - New York

Virginia

  • Virginia Commonwealth University Health System - Richmond

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2020-02-03
Est. Completion 2023-02-02

Sponsor

TransMedics

23 total trials

What the Registry Record Tells You About NCT05096754

The ClinicalTrials.gov registry entry for NCT05096754 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,454-participant average among 19 other Liver Transplant trials with a reported enrollment target (99% lower). The listed sponsor is TransMedics, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Transplant appearing as the primary indexed condition, and to 1 intervention - of which OCS Liver is the first listed.

NCT05096754 reports 11 study locations spanning 7 distinct geographic areas - top geographies include California, Texas, Maryland.

Frequently Asked Questions

What is clinical trial NCT05096754 about?

NCT05096754 is a clinical study titled "OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval Study". Post-approval observational study of subjects that were enrolled and transplanted in the OCS Liver PROTECT CAP.

What is the current status of trial NCT05096754?

This trial is currently completed. The enrollment target is 74 participants. The study started on 2020-02-03. Estimated completion is 2023-02-02.

What conditions does trial NCT05096754 study?

This clinical trial studies the following conditions: Liver Transplant.

What interventions are being tested in trial NCT05096754?

The interventions under investigation include: OCS Liver (DEVICE).

Who is sponsoring clinical trial NCT05096754?

This trial is sponsored by TransMedics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05096754 being conducted?

This trial has 11 study locations across California, Maryland, Massachusetts, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.